KIT and acute myeloid leukemia: Pazopanib, a receptor tyrosine kinase inhibitor (RTKI) of VEGFRs, PDGFRs, and cKit, was shown to be directly cytotoxic to AML cells, and to sensitize AML cells to chemotherapy by eliminating the refractory-disease effect of ECs 87.